PAMELA BINGHAM: Open Payments
NPI 1427444116 · BYRAM, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,273 in 49 payments from 15 companies in 2025. Trend: 2023 $992 · 2024 $1,016 · 2025 $1,273
Food & beverage: $1,273
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $305 |
| PFIZER INC. | 4 | $202 |
| Phathom Pharmaceuticals, Inc. | 2 | $145 |
| Lilly USA, LLC | 7 | $131 |
| AstraZeneca Pharmaceuticals LP | 7 | $128 |
| Supernus Pharmaceuticals, Inc. | 1 | $92 |
| GlaxoSmithKline, LLC. | 4 | $64 |
| Amgen Inc. | 3 | $58 |
| Novo Nordisk Inc | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $24 |
Products named: PREVNAR 20, VOQUEZNA, MOUNJARO, QULIPTA, VRAYLAR, BREZTRI, Qelbree, UBRELVY.
Industry payments across MS — which companies pay providers there.
